Upload
sergipujol
View
223
Download
0
Embed Size (px)
Citation preview
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 1/12
FP7-REGIONS-2010-1
AMI-4EUROPE
Advanced, Cross-Disciplinary &
Integrated Medical I maging for all
EU ropeans through a Network of
Regional Clusters and DevelOP ment
StratE gies
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 2/12
FP7-REGIONS-2010-1
AMI-4EUROPE: at a glance (1)
“Next Generation” of Medical Imaging is just here out of the integration and cross-disciplinary use of NanoMedicine, Pharma-cological breakthroughs, Biotechnologies for healthcare and ICT combined with standard
Medical Imaging evolution.Healthcare sector is quite diverse and collaboration has been difficult as a result, sothe challenge is to build expertise in the
development of integrated systems that address unmet clinical needs while providing asolid and consistent network of R&D +Innovation groups.
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 3/12
FP7-REGIONS-2010-1
AMI-4EUROPE: at a glance (1)
AMI-4EUROPE is to co-ordinate, integrateand set up a newly defined EU-based Value Chain on Advanced, Cross-disciplinary and Integrated Medical Imaging by taking full
advantage of all strengths that Europeanstakeholders have while targeting the market niches that are arising as the Next GenerationMedical Imaging unfolds itself
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 4/12
FP7-REGIONS-2010-1
AMI-4EUROPE: MEDICAL IMAGING RESEARCH AGENDAS
•
Cross-Disciplinary Integrated Medical Imaging :
– CLOUD MEDICAL IMAGING
– NANOTECHNOLOGIES, BIOMATERIALS AND THE USE OF
STEM CELLS AND TISSUE FOR CARDIOVASCULAR
DIAGNOSIS & TREATMENT
– ICT & IMAGING FOR ONCOLOGICAL DIFFERENTIAL
DIAGNOSIS
– NANOSCALE PHOTONIC IMAGING– PRODUCTION OF NEW MOLECULES AND RESEARCH OF
NEW MARKERS OF BIOLOGICAL PROCESSES
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 5/12
FP7-REGIONS-2010-1
AMI-4EUROPE: KEY VALUE-ADDED ISSUES
•
Regions with former experience oneconomic development throughhealth-related economy
• Strong technical expertise in the field
• Covering all major EU-27 areas +WBC + INCO
• Triple Helix in all regions + RDAsinvolved
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 6/12
FP7-REGIONS-2010-1
AMI-4EUROPE: GEOGRAPHICAL COVERAGE
+ Africa and LatinAmerica
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 7/12
FP7-REGIONS-2010-1
AMI-4EUROPE: MEDICAL IMAGING CURRENT EXPERTISE
•
Projects with socio-economic impactalready started by partners:
– CITE-C (Madrid)
– NANOCARDIO (Madrid)– USE OF STEM CELLS AND TISSUE FOR CARDIO-
VASCULAR DIAGNOSIS & TREATMENT (Hannover)
– ICT & IMAGING FOR ONCOLOGICAL DIFFERENTIAL
DIAGNOSIS (Hannover)
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 8/12
FP7-REGIONS-2010-1
AMI-4EUROPE: IMPACT & EXIT STRATEGY (1)
• An enabler for public (funding agencies) and private
enterprises to enter (on a sound information basis) intothe emerging field of Advanced Medical Imaging (AMI).
• Operationally geared to make Coordinating Action
most valuable to the stakeholders in the field.
• Business opportunities related to the wider field of
economic growth in a global context. A business plan
(WP 6) and private-public funding (WP 2) issues are
part of the project activities.
• A European and transnational level analysis will
leverage the conclusions to the European level.
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 9/12
FP7-REGIONS-2010-1
AMI-4EUROPE: IMPACT & EXIT STRATEGY (2)
• A knowledge transfer from 5 regional RDC to two
newly founded RDC (by coaching them and enabling )is conceived, thus creating new business
opportunities.
• Strong analysis of potential and anticipated impact in
the fields of regional up to international business opportunities are considered.
• Impact on policy making (lead markets, Pro Inno
initiative, EIT) is considered.
• The impact is aligned with the EU Commisions CIP
programm and with the ETP Nanomedecine initiative.
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 10/12
FP7-REGIONS-2010-1
AMI-4EUROPE: IMPACT & EXIT STRATEGY (3)
• A Business Plan in support of JAP and the overall AMI
strategy is to be defined, thus assuring maximumsynergy searching and mid and long-term sustaina-
bility.
• To integrate and coordinate outcomes and results
within the Europe INNOVA, PRO INNO Europe® andthe ETPs, to maximize synergies.
• AMI-TP Platform, AMI BackOffice, AMI DataWarehouse,
AMI Advisory Council and European Cluster for AMI are
to outlast the Project.
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 11/12
FP7-REGIONS-2010-1
AMI-4EUROPE: NEGOTIATION PHASE (1)
• Draft versions of DoW, budget breakdown, legal andfinancial data have been submitted and are in theprocess to be finalized.
• Budget adjustments have been made as per
indications received in Negotiation Mandate:– 60% flat rates down to 20%
– Detailed breakdowns by WP and activities provided
– Total requested funding reduced to the maximum amountindicated by the EC
• Project is comprehensive, challenging and broader in
scope. Thus, further budget reduction will result in loss
of outcomes and results.
8/3/2019 AMI-4EUROPE Presentation Brussels
http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 12/12
FP7-REGIONS-2010-1
AMI-4EUROPE: NEGOTIATION PHASE (2)
• OPEN ISSUES.
– Treatment of organizations participating under the“umbrella” of the Clusters
• Beneficiaries vs. Third Parties vs. Consultants
–Agreement on submitted budget and DoW
– Ways to proceed to “clear” pending legal issues with somebeneficiaries
– Consortium Agreement
– Tentative starting date
• ISSUES TO BE RAISED BY THE EC (if any).